Monte Rosa hits $37.5M milestone as Novartis starts Phase 2 trial for arthritis drug MRT-6160

Monte Rosa Therapeutics announced that Novartis has initiated a second Phase 2 clinical trial for MRT-6160 (DDY391), targeting moderate to severe psoriatic arthritis. This follows a prior Phase 2 trial in Sjögren's disease and triggers a $37.5 million milestone payment to Monte Rosa. The study aims to evaluate the drug's efficacy and safety in treating psoriatic arthritis, a chronic inflammatory disease with significant unmet needs. Monte Rosa and Novartis continue their collaboration under a global license agreement, with Monte Rosa eligible for further milestones and profit sharing as development progresses.

As of Oct 28, 2026 18:11 WIB, Novartis AG (NVS) shares are trading at USD 154.55 on Pluang, down 1.47% for the day. The stock sees a high volume of 3,734,180 shares and a typical hold time of 83 days among investors. Despite the recent milestone news, Pluang order activity remains heavily skewed towards selling at 98%.